Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Finckh

Showing results (41-50 of 225) with videos related to

Pageof 23
Sort By:
Clinical Therapeutics|June 15, 2019
Preferences of Patients and At-risk Individuals for Preventive Approaches to Rheumatoid ArthritisMarie Falahee, Axel Finckh, Karim Raza, et al.
Joint Bone Spine|July 10, 2012
Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: results from the Swiss SCQM registryPascal Zufferey, Jean Dudler, Almut Scherer, et al.
Rheumatology (Oxford, England)|January 25, 2011
The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort studyDiego Kyburz, Cem Gabay, Beat A Michel, et al.
Current Rheumatology Reports|July 13, 2016
Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient PreferencesAxel Finckh, Monica Escher, Matthew H Liang, et al.
Revue Medicale Suisse|March 8, 2018
[Microbiota and inflammatory rheumatisms]Matthias Jarlborg, Deshiré Alpizar-Rodriguez, Athan Baillet, et al.
Annals of the Rheumatic Diseases|December 4, 2020
Response to: 'Correspondence on '<i>Prevotella copri</i> in individuals at risk for rheumatoid arthritis'' by Sun and NiBenoît Thomas P Gilbert, Axel Finckh, Deshire Alpizar Rodriguez
Best Practice & Research. Clinical Rheumatology|February 24, 2009
The economics of treatment in early rheumatoid arthritisNick Bansback, Carlo A Marra, Axel Finckh, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 1, 2025
Addressing methodological concerns on the JAK-pot MACE analysisRomain Aymon, Delphine S Courvoisier, Axel Finckh, et al.
Clinical and Experimental Rheumatology|November 27, 2019
Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysisEvo Alemao, Roelien Postema, Yedid Elbez, et al.
Frontiers in Cellular and Infection Microbiology|December 11, 2020
Mini-Review: Human Microbiome and Rheumatic DiseasesMeltem Vural, Benoit Gilbert, Işıl Üstün, et al.
Pageof 23

Showing results (41-50 of 225) with videos related to

Sort By:
Pageof 23
Clinical Therapeutics|June 15, 2019
Preferences of Patients and At-risk Individuals for Preventive Approaches to Rheumatoid ArthritisMarie Falahee, Axel Finckh, Karim Raza, et al.
Joint Bone Spine|July 10, 2012
Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: results from the Swiss SCQM registryPascal Zufferey, Jean Dudler, Almut Scherer, et al.
Rheumatology (Oxford, England)|January 25, 2011
The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort studyDiego Kyburz, Cem Gabay, Beat A Michel, et al.
Current Rheumatology Reports|July 13, 2016
Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient PreferencesAxel Finckh, Monica Escher, Matthew H Liang, et al.
Revue Medicale Suisse|March 8, 2018
[Microbiota and inflammatory rheumatisms]Matthias Jarlborg, Deshiré Alpizar-Rodriguez, Athan Baillet, et al.
Annals of the Rheumatic Diseases|December 4, 2020
Response to: 'Correspondence on '<i>Prevotella copri</i> in individuals at risk for rheumatoid arthritis'' by Sun and NiBenoît Thomas P Gilbert, Axel Finckh, Deshire Alpizar Rodriguez
Best Practice & Research. Clinical Rheumatology|February 24, 2009
The economics of treatment in early rheumatoid arthritisNick Bansback, Carlo A Marra, Axel Finckh, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 1, 2025
Addressing methodological concerns on the JAK-pot MACE analysisRomain Aymon, Delphine S Courvoisier, Axel Finckh, et al.
Clinical and Experimental Rheumatology|November 27, 2019
Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysisEvo Alemao, Roelien Postema, Yedid Elbez, et al.
Frontiers in Cellular and Infection Microbiology|December 11, 2020
Mini-Review: Human Microbiome and Rheumatic DiseasesMeltem Vural, Benoit Gilbert, Işıl Üstün, et al.
Pageof 23